The Board of Directors of Celltrion, Inc. has authorized a buyback plan on June 14, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
181,800 KRW | -1.46% |
|
+2.83% | -9.78% |
Jul. 01 | S.Korean shares rise on robust data; battery, biopharma stocks jump | RE |
Jun. 17 | Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.78% | 27.02B | |
+16.59% | 44.44B | |
-10.62% | 37.68B | |
+41.93% | 39.84B | |
+29.92% | 31.46B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B | |
-14.80% | 10.38B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion, Inc. authorizes a Buyback Plan.